Articles from Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium

Geleen, May 19th, 2026

By Matisse Pharmaceuticals · Via GlobeNewswire · May 19, 2026

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

Geleen, December 11, 2025

By Matisse Pharmaceuticals · Via GlobeNewswire · December 11, 2025

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Geleen, November 13th, 2025.

By Matisse Pharmaceuticals · Via GlobeNewswire · November 13, 2025